A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

Clifford R Jack Jr, David A Bennett, Kaj Blennow, Maria C Carrillo, Howard H Feldman, Giovanni B Frisoni, Harald Hampel, William J Jagust, Keith A Johnson, David S Knopman, Ronald C Petersen, Philip Scheltens, Reisa A Sperling, Bruno Dubois, Clifford R Jack Jr, David A Bennett, Kaj Blennow, Maria C Carrillo, Howard H Feldman, Giovanni B Frisoni, Harald Hampel, William J Jagust, Keith A Johnson, David S Knopman, Ronald C Petersen, Philip Scheltens, Reisa A Sperling, Bruno Dubois

Abstract

Biomarkers have become an essential component of Alzheimer disease (AD) research and because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used in cognitive aging research. A number of current issues suggest that an unbiased descriptive classification scheme for these biomarkers would be useful. We propose the "A/T/N" system in which 7 major AD biomarkers are divided into 3 binary categories based on the nature of the pathophysiology that each measures. "A" refers to the value of a β-amyloid biomarker (amyloid PET or CSF Aβ42); "T," the value of a tau biomarker (CSF phospho tau, or tau PET); and "N," biomarkers of neurodegeneration or neuronal injury ([(18)F]-fluorodeoxyglucose-PET, structural MRI, or CSF total tau). Each biomarker category is rated as positive or negative. An individual score might appear as A+/T+/N-, or A+/T-/N-, etc. The A/T/N system includes the new modality tau PET. It is agnostic to the temporal ordering of mechanisms underlying AD pathogenesis. It includes all individuals in any population regardless of the mix of biomarker findings and therefore is suited to population studies of cognitive aging. It does not specify disease labels and thus is not a diagnostic classification system. It is a descriptive system for categorizing multidomain biomarker findings at the individual person level in a format that is easy to understand and use. Given the present lack of consensus among AD specialists on terminology across the clinically normal to dementia spectrum, a biomarker classification scheme will have broadest acceptance if it is independent from any one clinically defined diagnostic scheme.

© 2016 American Academy of Neurology.

Figures

Figure 1. Images of clinically normal individuals…
Figure 1. Images of clinically normal individuals and participants with AD
Individuals with AD dementia are clinically diagnosed participants in Mayo Alzheimer's Disease Research Center study while clinically normal individuals are participants in the Mayo Clinic Study of Aging. (A) FDG-PET of 75-year-old man with AD dementia. Hypometabolism in medial parietal and lateral temporal-parietal isocortex with relative preservation of frontal metabolism, which is characteristic of typical (multidomain amnestic) AD. (B) FDG-PET of clinically normal 71-year-old man. Uniform FDG uptake is present throughout the isocortex. (C) MRI of 71-year-old man with AD dementia. Atrophy is present in the medial temporal allocortex and the basal-lateral temporal isocortex, which is characteristic of typical (multidomain amnestic) AD. (D) MRI of clinically normal 71-year-old woman without atrophy. (E) Amyloid PET with Pittsburgh compound B of 71-year-old woman with AD dementia. Ligand uptake is seen throughout the isocortex. (F) Amyloid PET of clinically normal 93-year-old man showing no ligand uptake in the isocortex. AD = Alzheimer disease; FDG = [18F]-fluorodeoxyglucose.
Figure 2. Tau and amyloid PET imaging…
Figure 2. Tau and amyloid PET imaging in AD
A 79-year-old man with a clinical diagnosis of AD dementia. He is a participant in the Mayo Alzheimer's Disease Research Center study. (A, B) Coronal and axial tau PET images (AV1451) superimposed on MRI. (C, D) Coronal and axial Pittsburgh compound B PET images superimposed on MRI. The tau PET images (top) illustrate extensive tracer uptake in basal lateral temporal, parietal, and frontal isocortex with sparing of sensory motor and primary visual cortices. Off-target binding is seen in the basal ganglia, which is characteristic of this tracer. Although areas of spatial overlap between the tau and amyloid tracers are present, abundant amyloid tracer uptake is seen in the frontal lobes, but not with the tau tracer. Conversely, abundant uptake is seen in the medial temporal lobes with the tau ligand but not with the amyloid ligand. AD = Alzheimer disease.

References

    1. Dubois B, Feldman HH, Jacova C, et al. . Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014;13:614–629.
    1. Dubois B, Feldman HH, Jacova C, et al. . Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–746.
    1. Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280–292.
    1. Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association Workgroup. Alzheimers Dement 2011;7:270–279.
    1. McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association Workgroup. Alzheimers Dement 2011;7:263–269.
    1. Jack CR Jr, Albert MS, Knopman DS, et al. . Introduction to the recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:257–262.
    1. Hampel H, Frank R, Broich K, et al. . Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560–574.
    1. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol 2015;14:114–124.
    1. Marquie M, Normandin MD, Vanderburg CR, et al. . Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015;78:787–800.
    1. Johnson KA, Shultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer's disease. Ann Neurol 2016;79:110–119.
    1. Scholl M, Lockhart SN, Schonhaut DR, et al. . PET Imaging of tau deposition in the aging human brain. Neuron 2016;89:971–982.
    1. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70:960–969.
    1. Duyckaerts C, Braak H, Brion JP, et al. . PART is part of Alzheimer disease. Acta Neuropathol 2015;129:749–756.
    1. Duyckaerts C. Tau pathology in children and young adults: can you still be unconditionally baptist?. Acta Neuropathol 2011;121:145–147.
    1. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron 2013;80:1347–1358.
    1. Chetelat G. Alzheimer disease: Abeta-independent processes—rethinking preclinical AD. Nat Rev Neurol 2013;9:123–124.
    1. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008;60:534–542.
    1. Dubois B, Feldman HH, Jacova C, et al. . Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118–1127.
    1. Vos SJ, Verhey F, Frolich L, et al. . Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 2015;138:1327–1338.
    1. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009;66:200–208.
    1. Jack CR Jr, Knopman DS, Weigand SD, et al. . An operational approach to NIA-AA criteria for preclinical Alzheimer's disease. Ann Neurol 2012;71:765–775.
    1. Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306–319.
    1. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007;64:343–349.
    1. Mattsson N, Zetterberg H, Hansson O, et al. . CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385–393.
    1. Visser PJ, Verhey F, Knol DL, et al. . Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA Study: a prospective cohort study. Lancet Neurol 2009;8:619–627.
    1. Buerger K, Ewers M, Pirttila T, et al. . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006;129:3035–3041.
    1. Besson FL, La Joie R, Doeuvre L, et al. . Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer's disease. J Neurosci 2015;35:10402–10411.
    1. Jagust WJ, Landau SM, Shaw LM, et al. . Relationships between biomarkers in aging and dementia. Neurology 2009;73:1193–1199.
    1. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652–656.
    1. Tapiola T, Alafuzoff I, Herukka SK, et al. . Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382–389.
    1. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. . Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630–1645.
    1. Hong YT, Veenith T, Dewar D, et al. . Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol 2014;71:23–31.
    1. Krut JJ, Zetterberg H, Blennow K, et al. . Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. J Neurol 2013;260:620–626.
    1. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2003;18:186–190.
    1. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231–245.
    1. Olsson A, Vanderstichele H, Andreasen N, et al. . Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336–345.
    1. Hall S, Ohrfelt A, Constantinescu R, et al. . Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445–1452.
    1. Hesse C, Rosengren L, Andreasen N, et al. . Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001;297:187–190.
    1. Ost M, Nylen K, Csajbok L, et al. . Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 2006;67:1600–1604.
    1. Skillback T, Rosen C, Asztely F, Mattsson N, Blennow K, Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol 2014;71:476–483.
    1. Buerger K, Otto M, Teipel SJ, et al. . Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging 2006;27:10–15.
    1. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605–613.
    1. Fotuhi M, Do D, Jack C. Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol 2012;8:189–202.
    1. Crary JF, Trojanowski JQ, Schneider JA, et al. . Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014;128:755–766.
    1. Josephs KA, Duffy JR, Fossett TR, et al. . Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants. Arch Neurol 2010;67:596–605.
    1. Wirth M, Villeneuve S, Haase CM, et al. . Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 2013;70:1512–1519.
    1. Rabinovici GD, Jagust WJ, Furst AJ, et al. . Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008;64:388–401.
    1. Alexopoulos P, Kriett L, Haller B, et al. . Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. Alzheimers Dement 2014;10:684–689.
    1. De Meyer G, Shapiro F, Vanderstichele H, et al. . Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010;67:949–956.
    1. Whitworth JA. 2003 World Health Organization (WHO)/International Society of hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983–1992.
    1. Murray ME, Lowe VJ, Graff-Radford NR, et al. . Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 2015;138:1370–1381.
    1. Thal DR, Beach TG, Zanette M, et al. . [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement 2015;11:975–985.
    1. Wright JT Jr, Williamson JD, Whelton PK, et al. . A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–2116.
    1. Grasbeck R. The evolution of the reference value concept. Clin Chem Lab Med 2004;42:692–697.
    1. Knopman DS, Jack CR Jr, Wiste HJ, et al. . Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576–1582.
    1. Klunk WE, Koeppe RA, Price JC, et al. . The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 2015;11:1–15.
    1. Whitwell JL, Josephs KA, Murray ME, et al. . MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008;71:743–749.
    1. Hampel H, Schneider LS, Giacobini E, et al. . Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother 2015;15:83–105.
    1. Portelius E, Zetterberg H, Skillback T, et al. . Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain 2015;138:3373–3385.
    1. Villeneuve S, Reed BR, Madison CM, et al. . Vascular risk and Abeta interact to reduce cortical thickness in AD vulnerable brain regions. Neurology 2014;83:40–47.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa